MeiraGTx Holdings plc has entered into agreements for a strategic investment totaling up to $400 million from Oberland Capital. The investment includes up to $375 million in non-dilutive capital through royalty notes and up to $25 million in equity. An initial $135 million has been funded, consisting of $125 million for royalties and $10 million in equity. Additional tranches of $50 million each are available at MeiraGTx's option, contingent on positive data readouts for AAV-hAQP1 (Phase 2 AQUAx2 study in 2027) and regulatory approvals for bota-vec (2027) and AAV-hAQP1 (2028). A further $100 million is available upon mutual agreement for new products or business development. Oberland Capital also has the right to purchase an additional $15 million in equity. The proceeds will be used for working capital, repayment of existing debt, and general business purposes. The company has redeemed in full its outstanding notes under the Perceptive NPA, terminating that agreement without early termination penalties.